ADHD 2 | The REACH Institute

New treatments for ADHD

By The REACH Institute | January 21, 2022

Newer treatments approved by the Food and Drug Administration (FDA) for pediatric patients with attention-deficit/hyperactivity disorder (ADHD) include two medications that address some of the common issues families have with standard stimulant treatments. Another development is use of devices to manage ADHD symptoms.

Getting smarter about child mental health

By The REACH Institute | June 12, 2018

“For these straightforward cases, when you can identify uncomplicated ADHD in patients without co-occuring depression or anxiety – well, everyone in primary care should be able to do this.”